Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SORD | Q00796 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28562329 | 0.84 | RET (0.42) | ACHECYP3A4 | |
| SCHEMBL20745663 | 0.82 | SORD (0.41) | SORDPTPN11MEN1KMT2AAOC3 | |
| SCHEMBL22320365 | 0.80 | EGFR (0.42) | ALDH1A1HSD17B10SORDPTPN11CYP3A4 | |
| SCHEMBL22389879 | 0.80 | PANK3 (0.50) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20745046 | 0.77 | AOC3 (0.37) | KDM4EHSD17B10SORDPTPN11CYP3A4 | |
| SCHEMBL20746494 | 0.76 | TRPV3 (0.42) | SORDAOC3ACACBPANK3 | |
| SCHEMBL7386664 | 0.75 | PANK3 (0.48) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20746025 | 0.74 | DYRK1A (0.41) | ALDH1A1HPGDHSD17B10SORDCYP3A4 | |
| SCHEMBL22262720 | 0.74 | ACHE (0.39) | ACHESORDACACB | |
| SCHEMBL16815333 | 0.73 | ACHE (0.50) | ACHESORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ACHE 4299/4885KDM4E 1735/4885ALDH1A1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.